Openwater to Showcase Non-Invasive Diagnostic and Neuromodulation Technology at the 2025 Society for Neuroscience Annual Meeting
The company will showcase its flagship devices, Open-Motion and Open-LIFU, at booth #3430
​
-
Openwater will exhibit its diagnostic and neuromodulation devices at the 2025 Society for Neuroscience Annual Meeting, including Open-Motion and Open-LIFU.
-
Open-Motion is Openwater’s diagnostic imaging system, validated in studies at Brown University and the University of Pennsylvania for severe stroke detection.
-
Open-LIFU is Openwater’s focused ultrasound system, enabling noninvasive neuromodulation, shown effective in long COVID, cancer, and depression research, and recently adopted by MIT for studies on human consciousness.
San Francisco, Calif. - Oct. 31, 2025 - Openwater, an open-source medical technology company delivering portable, hospital-grade diagnostic and therapeutic devices, will exhibit its Open-Motion and Open-LIFU platforms at the Society for Neuroscience (SfN) Annual Meeting in San Diego, CA, on November 15-19. The devices use ultrasound and infrared light technology to noninvasively assess and modulate brain activity, expanding possibilities for neurological research and care.
Attendees are invited to visit with the Openwater team at booth #3430 to learn more about the technologies:
-
Open-Motion - The portable diagnostic system utilizes near-infrared light to measure and track blood flow and volume beneath the tissue surface, giving researchers and clinicians a new way to visualize brain activity without the bulk or cost of traditional imaging devices. Adopted in the U.S. and internationally, clinical studies out of Brown University and the University of Pennsylvania have demonstrated Open-Motion’s ability to detect severe stroke.
-
Open-LIFU - A low-intensity focused ultrasound system designed for targeted neuromodulation. Through the delivery of precise sound waves, researchers and clinicians are able to modulate activity deep within the brain without the need for implants or surgery. Prior research has explored LIFU’s potential in areas including addiction, pain, and depression. Openwater recently partnered with MIT’s Lincoln Laboratory to deploy the device in studies of human consciousness.
“Focused ultrasound offers us a new window into the brain that can non-invasively influence function.” said Aaron Timm, CEO at Openwater. “We’re excited to share our platforms with the SfN community and show how we’re translating the promise of neuromodulation into meaningful advancements in neurological research.”
Openwater champions open-source principles, providing software, hardware, patents, and safety data for users to access and build upon. With this forward-thinking business model, Openwater hopes to speed up innovation and lower costs in clinical research to ultimately deliver effective and affordable treatments to patients faster.
To learn more about Openwater and its open-source devices, visit www.openwater.health.
About Openwater
Openwater is an AI-driven medical technology company founded by Dr. Mary Lou Jepsen to make hospital-grade care universally accessible. Backed by notable supporters including Khosla Ventures, Plum Alley, BOLD Capital Partners, Vitalik Buterin, Esther Dyson, and Peter Gabriel, Openwater employs open-source development and consumer electronics manufacturing to lower the cost and speed the delivery of non-invasive medical devices. The company collaborates with leading institutions worldwide to research, validate, and distribute these technologies, aiming to reach patients across borders and income levels.
Media Contact
Alaina Chiappone